Iovance Biotherapeutics, Inc. (0JDK.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Iovance Biotherapeutics, Inc.
Address
825 Industrial Road
San Carlos, CA 94070
United States of America (the)
Phone
650 260 7120
Website
Sector
Healthcare
Industry
Biotechnology
Employees
838
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Frederick G. Vogt | Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director | 1.13M | 1974 |
| Elma S. Hawkins | Advisor to the Board | 465,395 | 1957 |
| Corleen Roche | Chief Financial Officer | 494,150 | 1966 |
| Igor Bilinsky | Chief Operating Officer | 738,374 | 1973 |
| Friedrich Graf Finckenstein | Chief Medical Officer | 764,634 | 1967 |
| Daniel G. Kirby | Chief Commercial Officer | 804,031 | 1972 |
| Raj K. Puri | Chief Regulatory Officer | 867,158 | 1956 |
| Brian Gastman | Executive Vice President of Medical Affairs | 0 | N/A |
| Brian Shew | Senior Vice President & Head of Digital and Information Technology | 0 | N/A |
| Matthew W. Rosinack | Principal Accounting Officer | 0 | 1972 |
| Howard Johnson | Chief Business Officer | 0 | 1960 |
| Kevin Smyth | Executive Vice President of Quality | 0 | N/A |
| Tracy Winton | Executive Vice President of Human Resources | 0 | N/A |
| Marc R. Theoret | Senior Vice President of Regulatory Strategy | 0 | N/A |
| Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
Description
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to identify and eradicate cancerous cells. The company currently oversees six ongoing Phase 2 clinical trials. Notably, its primary therapeutic candidate, lifileucel, is under investigation in two of these studies: C-144-01 for advanced melanoma and C-145-04 for cervical cancer that is recurrent, metastatic, or persistent. Furthermore, another candidate, LN-145, is being assessed in study C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics maintains strategic alliances and licensing arrangements with esteemed institutions including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Incorporated in 2007 and situated in San Carlos, California, the organization was formerly known as Lion Biotechnologies, Inc. until its rebranding in June 2017.
